LEO’s Enstilar® foam spray shown to improve quality of life for psoriasis patients

pharmafield logo - pharma news

LEO Pharma has announced new data which provide further evidence of the difference that Enstilar® foam spray can make to the lives of people with psoriasis.

The data, announced at the 25th European Academy of Dermatology and Venereology (EADV) congress, show that improved skin clearance with Enstilar® foam spray (calcipotriol/betamethasone dipropionate 50 micrograms/g + 0.5 mg/g) leads to increased quality of life (QoL) in adult patients with psoriasis vulgaris (also known as plaque psoriasis). 

The data presented at the EADV congress are the results of a post-hoc analysis of the Phase III, 12-week study, PSO-ABLE.  In the post-hoc analysis, patients’ Dermatology Life Quality Index (DLQI) score was assessed against a measure of skin clearance (excluding the head, which was left untreated) demonstrated by a reduction in modified Psoriasis Area and Severity Index (mPASI) of 50–<75%, 75–<90% or 90% at week 4.    

Psoriasis vulgaris is the most common clinical form of psoriasis, and is estimated to affect up to 2 million people nationwide, with men and women equally likely to be affected.  

It is a chronic, debilitating disease, and patients with inadequately managed psoriasis can experience substantial burden of illness, with similar reductions in quality of life to those experienced by patients living with diabetes or cancer. As a result of their psoriasis, one in three patients has experienced depression and/or anxiety and one in 10 has contemplated suicide.  

Professor Chris Griffiths, study lead, said: “The study analysis finally provides good evidence for a correlation between improved skin clearance and increased quality of life in psoriasis. These data show that the benefits of treatment with Enstilar® extend beyond the solely physical.”

Gitte Aabo, President and CEO of LEO Pharma, said: “The emotional impact of psoriasis can be just as profound, with more than three-quarters of people saying psoriasis affects their quality of life. This data emphasises just how important getting the right treatment and formulation is to improve both physical and mental wellbeing, and how Enstilar® aims to help achieve that.”